Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2010

View Archived Issues

Roche claims new tachykinin NK3 receptor antagonists

Genz-123346 inhibits cystogenesis in models of polycystic kidney disease

GSK identifies new macrolide inhibitors of IL-6 production

Karus Therapeutics presents new HDAC inhibitors

Emory University discloses new NMDA receptor antagonists

Potentiometric detection of membrane-bound sialic acid shows promise to diagnose cancer

Hyperglycemia correlates with low SHBG levels in androgenetic alopecia

Combination of first-line bevacizumab and chemotherapy is safe in NSCLC

SNPs in IL17RA and IL17A genes may associate with alopecia areata phenotype

Advaxis completes dosing initial group in phase II ADXS11-001 trial in cervical dysplasia

Rush University Medical Center participates in phase II MGAWN1 trial in West Nile virus infection

Curaxis provides update on Memryte development for Alzheimer's disease

Evotec Neurosciences presents new histamine H3 receptor antagonists

EMA accepts Optimer Pharma's fidaxomicin MAA for review

FDA grants priority review for Benlysta BLA in SLE

U.S. scientists identify new cromolyn derivatives

Chelsea Therapeutics' droxidopa enters phase II trial in chronic fatigue syndrome

FDA grants orphan drug status to ACE-031 for Duchenne's muscular dystrophy

FDA advisory committee recommends expanding pain indications for Cymbalta

SRI International and Taiho furthering development of TAS-108 for breast cancer

Reconstituted HDL suppresses inflammation-induced angiogenesis in vitro

Cellmid's midkine-directed antibodies CDY-91 and CDY-92 reduce disease severity in MS model

Vertex Pharma provides update on recent clinical developments

Celgene receives marketing authorization in Japan for Revlimid

University of Pittsburgh receives NCI grant to develop agents for head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...